Skip to main content
Equibles

Andres Maldonado

Analyst

H.C. Wainwright

Equibles does not estimate personal net worth.

About Andres Maldonado

Andres Maldonado is recorded as Analyst at H.C. Wainwright. Andres Maldonado has spoken on 1 earnings call and 3 other investor events across 4 companies, most recently for Relmada Therapeutics, Inc. on November 12, 2026. Those appearances were for Relmada Therapeutics, Inc. (RLMD), Immunome Inc. (IMNM), Verastem, Inc. (VSTM) and Zentalis Pharmaceuticals, Inc. (ZNTL). The companies whose calls Andres Maldonado spoke on are classified in the Healthcare sector.

Andres Maldonado on recent calls

“Just reading into the press release, the first one is, you know, both patients who progressed to muscle-invasive disease, you know, since they entered with T1 disease, the question is, you know, were there earlier warning signs, and does that change how you would select or monitor for these T1 patients coming up?”
Analyst — HC Wainwright & Co., Third Quarter 2026 Earnings Call ·
“I'd like to welcome everybody back to the H.C. Wainwright's 28th Annual Global Investment Conference. My name is Andres Maldonado. I'm a senior biotech analyst here at the firm, and it's my pleasure to welcome you.”
Analyst — H.C. Wainwright, H.C. Wainwright 28th Annual Global Investment Conference ·
“First off, from a mechanistic perspective, can you give us a little bit more color as to why cituximab appears to, you know, drive that deeper response we saw with the sub-therapeutic dose, specifically 400 mgs in PDAC.”
Analyst — H.C. Wainwright, Verastem Oncology VS-7375 TARGET-D Conference Call ·
“I'd like to welcome everybody back to H.C. Wainwright's BioConnect conference. We're going to start continuing it with our afternoon session. My name is Andres Maldonado.”
Analyst — H.C. Wainwright, H.C. Wainwright 4th Annual BioConnect Conference at Nasdaq ·

Affiliation history

  • H.C. Wainwright

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity